Abstract
Á2.
Patients then received IV Fe (200 mg) and were was based on algorithms, which were designed to provide an reviewed after 4 weeks according to Hb. efficient use of Epo by treating any iron deficiency prior to
Results. The median haemoglobin increased from 11.0 an increase in the Epo dose. The entire CAPD population (Inter quartile range, IQR, 10.1-12.6) g/dl to 11.7 (including patients on dialysis for <90 days) was managed (11.0-12.7) g/dl (P=0.06). The proportion of patients using this system. This study is therefore an investigation with absolute iron deficiency (ferritin <100 ng/ml ) into the dynamics of anaemia management in a CAPD decreased from 24 to 2%. The percentage of hypo-population. Patients who did not require Epo are included chromic red cells (%HRC ) decreased from 4 (2-7) to in the data set. Any new patients entering the dialysis 1 (1-4) (P<0.01).
programme were enrolled. Patients left the system when transplanted, converted to haemodialysis, transferred to
Conclusions. An integrated Epo and IV Fe policy another hospital, or by recovery of renal function or through increased the number of patients reaching the patient death. A total of 103 patients were managed in the European guideline from 50 to 75% with no increase study period. Screening in terms of weekly creatinine clearin the population median Epo requirements (42 (IQR, ance, residual renal function, parathyroid hormone levels, 25-95) IU/kg/week vs 45 (27-101) (P=NS)). This C-reactive protein, the presence of neoplasia, blood pressure study demonstrates the benefit of early (proactive) and CAPD peritonitis continued (without changes) throughintervention in achieving population compliance within out the two phases of the study. Manual blood pressure was current guidelines for renal anaemia.
recorded at each outpatient visit and logged on the computer system. Blood pressure trends were reviewed at the time of Keywords: clinical governance; erythropoietin; haemo-Epo or iron prescription and also at routine monthly multidisciplinary unit meetings. Particularly noticeable changes in globin; iron deficiency; iron sucrose; peritoneal dialysis blood pressure would be brought to attention by the nursing staff and blood pressure would be controlled primarily through weight reduction (PD ultrafiltration) but also using antihypertensive medications if necessary.
(11.0 g/dl ). The haemoglobin level above which erythropoieEpo dose was not increased if the patient was hypertensive (diastolic BP >99 mmHg). Blood pressure would be contin therapy would be decreased was designated the 'ceiling'. Therapy was decreased in a graded fashion depending on trolled and anaemia treatment considered at the subsequent review date. When an Hb of 11.0 g/dl was achieved, iron how high the haemoglobin had risen (ceilings of 13 and 15.5 g/dl ) (vide infra).
replacement continued according to protocol but there was no further increase in Epo therapy. Outpatient blood results were processed to provide recommendations for best subsequent therapy in terms of change to Epo dose or possible intravenous iron replacement. The algorithm used haemoglobin, ferritin and %HRC. Serum Statistics ferritin was measured by immunoassay (Bayer Immuno-1). Hb and %HRC were measured on a Technicon H*2 autoStatistical significance was assessed using the mated blood count analyser. Review and alterations to U-Mann-Whitney test for unpaired non-parametric data. therapy were managed through a single clinician and the Differences in variance were tested for using the F test CAPD nursing staff. The clinician (D.R.) monitored the (variance ratio test). recommendation of the algorithm and assessed the patient records for hypertension, resistant iron deficiency, resistant anaemia and raised inflammatory markers. The protocol was followed unless a specific clinical reason for deviation could be detected and recorded.
Results
Oral iron (ferrous sulphate) was used routinely in our CAPD population prior to the study. Patients received
The outcome for Hb, ferritin, %HRC and Epo doses 3×200 mg/day or the maximum dose they could tolerate.
is given in Table 1 . All results are given as median and
Oral iron was discontinued once the first IV Fe dose had been prescribed. The prior duration of oral therapy varied inter-quartile ranges.
from weeks to years. No minimum or maximum duration A total of 81 of the 103 CAPD patients received at for oral iron therapy was used as a criterion for inclusion in least one intravenous iron infusion during the 13 the study. months of study. No adverse reactions to iron sucrose The algorithms were altered in the light of experience over were encountered during this period. In phase 1, a 13 months and this produced two phases of development. mean of 18% of the CAPD population received an The sets of algorithms are available from the authors on iron infusion (300 mg) each month. In phase 2 this request.
increased to 35% receiving a lower dose infusion (200 mg) each month. During the study, a mean of Iron protocols 15% of patients did not require Epo. The proportion of patients with absolute iron deficiency (ferritin Phase 1 (0-8 months) (reactive) <100 ng/ml ) decreased from 24% (16/68) to 2% (1/66) ( Figure 1 ). The number of patients reaching the Patients with markers of iron deficiency (ferritin <100 ng/ml, European Renal Association guideline (>11.0 g/dl ) or ferritin 100-500 and %HRC Á5) were converted from increased from 51 to 76% ( Figure 2 ) with no increase oral iron to IV Fe (300 mg diluted in 250 ml, infused initially in the population Epo requirements (median 42 (IQR, at 60 ml/h for 10 mins, and then 120 ml/h for 1 h and 25-95) IU/kg/week vs 45 (27-101) (P=NS )). The ( UK Renal Association recommendation [3] 85% >10.0 g/dl ) increased from 78 to 92% (no 90 day Phase 2 (9-13 months) (proactive) exclusion). The prevalence of functional iron deficiency assessed using %HRC decreased (median 4 (IQR, 2-7)
The criteria for iron therapy were extended: ferritin to 1 (1-4) (P<0.01)), particularly during phase 2 <150 ng/ml, or ferritin 150-500 and %HRC Á2. Patients (ending month 13; Figure 3 ). ficant ( F test: SD 1.93 and 1.49, n 1 : 71, n 2 : 66, P= 0.1). In the context of the US criteria (target haematocrit 33-36%): at the end of the second phase, 20% Epo protocol (n=13) of Hb values were >13.0 g/dl (Hct 39%). All erythropoietin was administered by the subcutaneous However, 46% (n=6) of these patients were not on route. Patients who remained anaemic (Hb <11.0g/dl ) des-Epo at all and another 23% (n=3) had values >13.0 pite satisfactory markers for stored iron (as defined in each in at least one of the preceding 2 months. The phase) were commenced on Epo (starting dose: 1000 IU×3 remaining 31% (three patients) with Hb persistently per week) or received monthly incremental doses of Epo >13.0 g/dl had Epo dose decrements made in each of (increased by 1000 IU/dose administered, with an upper limit the three preceding months with a resultant mean Epo set at 300 IU/kg/week [3]). Epo doses were decreased in a dose of 2000 IU/week. The inference is that only three similar stepwise manner when the Hb >13.0g/dl. Above of 66 patients (4.5%) at 13 months had rolling Hb 15 .5 g/dl, the Epo dose was halved to the nearest 1000 values >13.0 g/dl, with consequences for reimburse-IU/dose delivered. At doses of 3000 IU/week, any decrement was of 1000 IU/week. ment of Epo costs in the US healthcare environment. Intravenous iron dextran has been shown to increase the haemoglobin response to Epo compared to oral iron or no iron therapy in a randomized controlled study [7] in haemodialysis patients. However, intravenous iron is more expensive than oral iron and has the added potential complications of anaphylaxis, cardiac toxicity and an increase in infective complications [8] . Side-effects consisting of metallic taste, nausea, vomiting, headache and hypotension are more commonly recognized. Intravenous iron sucrose has been demonstrated as an effective [9,10] and safe [11] supplement for the treatment of iron deficiency in haemodialysis patients and peritoneal dialysis patients [12] . Iron therapy can now be delivered to those with signs of absolute or functional iron deficiency (as assessed by ferritin and %HRC [9] ). This allows tailoring of iron therapy to those that may be expected to respond, and reduces the potential complication of iron overload by unlikely to respond. Certain discrimination of iron deficiency or iron overload has proved difficult if not impossible without resort to bone marrow examinaDiscussion tion. Currently the best available tests are ferritin and the percentage of hypochromic red cells in the circulation. In normal subjects, serum ferritin is an accurate Oral iron is associated with gastrointestinal side effects and is poorly absorbed in renal failure. This may be indicator of the total reticuloendothelial iron store [13] . Absolute iron deficiency in normal subjects is through intolerance, non-compliance [4], malabsorption [5] or through the excessive blood loss [6 ] that currently defined by a serum ferritin <20 mg/l. In renal failure the threshold for serum ferritin that defines iron occurs with the use of an extra-corporeal circuit. deficiency has been found to be at a greater level than controlled study, the proactive approach to normalization of %HRC in the CAPD population showed greater in normal subjects (50-100 ng/ml ) [14, 15] . An upper benefit in terms of improvements in %HRC and ferritin limit ferritin level of 500 ng/ml for iron therapy has outcome. Indeed, restricting intravenous iron therapy been proposed to avoid iron overload [16 ] , there being to those individuals with %HRC >10% would result little evidence in the literature of benefit from intravenin <10% of our CAPD population being offered this ous iron therapy above this level.
treatment at any one time ( Figure 1 ), resulting in no Functional iron deficiency is diagnosed when there opportunity for influencing the prevalence of iron is a normal serum ferritin concentration, but insuffideficiency in the group as a whole. These results are cient iron available to meet the needs of erythropoiesis.
entirely consistent with our studies in a large haemodiaRed cell hypochromia of >10% has been proposed as lysis population [17] . a marker of functional iron deficiency but response to These data indicate for ferritin and %HRC, in intravenous iron at lower levels has been documented particular, just how far the 'aim' must exceed the [9]. Indeed the upper limit for %HRC is 2.5%. %HRC desired (target) outcome in the systematic management can also be increased secondary to factors other than of renal anaemia in CAPD patient groups. Waiting for iron deficiency. Prolonged sample storage (more than clearly pathological levels to develop in either variable a few hours), sepsis, inflammation and haemolysis are before beginning therapy does not produce a satisfactall associated with higher values. The European guide-ory outcome. Further work is necessary to define the lines [1] (6A and B) for assessing and optimizing iron characteristics of the most effective system for manstores suggest that the ferritin should be maintained at aging renal anaemia in CAPD cohorts. >100 ng/ml, and the %HRC <10%. It is suggested that it is necessary to aim for optimal levels of ferritin Acknowledgements. at 200-500 ng/ml and %HRC <2.5%. Using a %HRC of Á5% and a ferritin level of <100 ng/ml as the criteria for intravenous iron therapy in the reactive References phase (1) of our study had no effect on %HRC as an 'prevention paradox' is described, wherein more isch-12. Domrongkitchaiporn S, Jirakranont B, Atamasrikul K, aemic events are prevented and more lives saved by
